AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11385384 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (10(‐8), 10(‐7), 10(‐6), and 10(‐5) mol/L)
Number of subjects: 10
Study 11385384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.5 and 1.0 microg. kg(‐1). min(‐1))
Number of subjects: 10
Study 11385384 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine (Control)
Number of subjects: 10
Study 11385384 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (Control)
Number of subjects: 10
Study 9524875 — intervention group
Group type: EXPERIMENTAL
Intervention: Equivalent Scores (ES) standardized tests
Number of subjects: 0
Study 9524875 — intervention group
Group type: EXPERIMENTAL
Intervention: Battery of 10 ES-standardized tests
Number of subjects: 0
Study 9524875 — intervention group
Group type: EXPERIMENTAL
Intervention: General indications concerning normality threshold
Number of subjects: 0
Study 8281589 — intervention group
Group type: EXPERIMENTAL
Intervention: Full lateral position
Number of subjects: 88
Study 8281589 — intervention group
Group type: COMPARATOR
Intervention: Wedged supine position
Number of subjects: 88
Study 3105681 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinch skin grafts
Number of subjects: 53
Study 3105681 — intervention group
Group type: COMPARATOR
Intervention: Porcine dermis
Number of subjects: 53
Study 30094437 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat protein (25 g protein) for 19 days
Number of subjects: 0
Study 30094437 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 19 days
Number of subjects: 0
Study 26803276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 117
Study 26803276 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 117
Study 24920942 — intervention group
Group type: EXPERIMENTAL
Intervention: Coload (15 ml/kg of crystalloid after intrathecal injection)
Number of subjects: 60
Study 24920942 — intervention group
Group type: COMPARATOR
Intervention: Preload (15 ml/kg of crystalloid before intrathecal injection)
Number of subjects: 60
Study 24920942 — intervention group
Group type: EXPERIMENTAL
Intervention: Coload
Number of subjects: 60
Study 24920942 — intervention group
Group type: COMPARATOR
Intervention: Preload
Number of subjects: 60
Study 22419728 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg iv zoledronate
Number of subjects: 43
Study 22419728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 20641122 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (PC)
Number of subjects: 43
Study 19370949 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 200
Study 19370949 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Intubation
Number of subjects: 200
Study 15936878 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed subjects
Number of subjects: 14
Study 15936878 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study 14517524 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (0.35 mg/kg/d) and/or prednisolone (2 mg/kg/day)
Number of subjects: 179
Study 14517524 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 179
Study 14517524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 11933340 — intervention group
Group type: EXPERIMENTAL
Intervention: Charing Cross system (CX4L)
Number of subjects: 149
Study 11933340 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Charing Cross system (Parema)
Number of subjects: 149
Study 11933340 — intervention group
Group type: EXPERIMENTAL
Intervention: Robinson Ultra Four (Robinson)
Number of subjects: 149
Study 11933340 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall healing rates
Number of subjects: 149
Study 9504181 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF treatment (0.02%, 0.05% or 0.1%)
Number of subjects: 0
Study 9504181 — intervention group
Group type: COMPARATOR
Intervention: Control (other mouthrinses containing xylitol, sorbitol, sacarine, ciclamate, aspartame, chlorhexidine, hexetidine)
Number of subjects: 0
Study 8368193 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief lecture dispelling myths about hypnosis and modified HGSHS:A
Number of subjects: 687
Study 8368193 — intervention group
Group type: COMPARATOR
Intervention: Standard version of HGSHS:A
Number of subjects: 687
Study 2878675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 515
Study 2878675 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 515
Study 2878675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Metoprolol combined
Number of subjects: 515
Study 2878675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (in patients pretreated with a beta blocker)
Number of subjects: 515
Study 31698917 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose-derived stromal cell (ASC) therapy
Number of subjects: 60
Study 31698917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28453471 — intervention group
Group type: EXPERIMENTAL
Intervention: ELND005 (scyllo-Inositol) 250 mg twice daily (BID)
Number of subjects: 0
Study 28453471 — intervention group
Group type: EXPERIMENTAL
Intervention: ELND005 (scyllo-Inositol) 250 mg once daily (QD)
Number of subjects: 0
Study 28453471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24047539 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept combined with FOLFIRI
Number of subjects: 0
Study 24047539 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI + placebo
Number of subjects: 0
Study 21045172 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey (0.3 g/kg lean body mass)
Number of subjects: 17
Study 21045172 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein (0.3 g/kg lean body mass)
Number of subjects: 17
Study 21045172 — intervention group
Group type: COMPARATOR
Intervention: Control (noncaloric drink)
Number of subjects: 17
Study 19681415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine pre-treatment (10 mg in 1.0 ml saline) under tourniquet for 30 seconds before propofol injection.
Number of subjects: 188
Study 19681415 — intervention group
Group type: COMPARATOR
Intervention: Ketamine added to propofol (10 mg in 9 ml propofol mixed with 1.0 ml saline).
Number of subjects: 188
Study 16696744 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 mug daily self-injection for a median of 19 months, with daily oral supplements of 1,000 mg calcium and 400 to 1,200 IU vitamin D.
Number of subjects: 1085
Study 16696744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1085
Study 16696744 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 1085
Study 12955294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 206
Study 12955294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 11397884 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 32
Study 11397884 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 32
Study 11397884 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (both doses)
Number of subjects: 32
Study 11397884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9777817 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 1105
Study 9777817 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 1105
Study 9777817 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 1105
Study 9777817 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 1105
Study 9777817 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1105
Study 9777817 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1105
Study 9777817 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect treatment for renin profile but correct for age-race subgroup
Number of subjects: 1105
Study 7889894 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐85 2 g twice daily
Number of subjects: 95
Study 7889894 — intervention group
Group type: COMPARATOR
Intervention: Corn oil 2 g twice daily (placebo)
Number of subjects: 95
Study 3065571 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.125% eye drops
Number of subjects: 20
Study 31732234 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention group (n=35)
Number of subjects: 71
Study 30453950 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri V3401 (5 × 10^9 CFU daily)
Number of subjects: 60
Study 30453950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28157261 — intervention group
Group type: EXPERIMENTAL
Intervention: MG-assisted TSP
Number of subjects: 31
Study 28157261 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopically guided TSP
Number of subjects: 31
Study 25286887 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (five sessions over two weeks)
Number of subjects: 36
Study 25286887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-groups of the training group (3000 meter group, 4x4-minutes high-intensity interval group, continuous training group)
Number of subjects: 36
Study 25286887 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline running performance
Number of subjects: 36
Study 23129021 — intervention group
Group type: EXPERIMENTAL
Intervention: Online
Number of subjects: 159
Study 23129021 — intervention group
Group type: EXPERIMENTAL
Intervention: Resources
Number of subjects: 159
Study 23129021 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 159
Study 21273603 — intervention group
Group type: EXPERIMENTAL
Intervention: CCND1 rs9344 genotype (G allele carriers: GG or AG)
Number of subjects: 620
Study 21273603 — intervention group
Group type: COMPARATOR
Intervention: Control group (AA wild-type genotype)
Number of subjects: 620
Study 21273603 — intervention group
Group type: EXPERIMENTAL
Intervention: CCND1 rs9344 genotype
Number of subjects: 620
Study 19484585 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammotome system
Number of subjects: 233
Study 19484585 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacora system
Number of subjects: 233
Study 16968574 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone prolonged-release 150-450 mg/day (n = 62)
Number of subjects: 122
Study 16968574 — intervention group
Group type: COMPARATOR
Intervention: Sertraline 50-100 mg/day (n = 60)
Number of subjects: 122
Study 16968574 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone prolonged-release
Number of subjects: 122
Study 16968574 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 122
Study 15351368 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor evoked potential (MEP) study
Number of subjects: 39
Study 15351368 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potential (SEP) study
Number of subjects: 39
Study 15351368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MEP and SEP
Number of subjects: 39
Study 11049800 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral miltefosine, 50 mg given twice daily for 14 days (group A)
Number of subjects: 54
Study 11049800 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral miltefosine, 50 mg given twice daily for 21 days (group B)
Number of subjects: 54
Study 11049800 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral miltefosine, 50 mg given twice daily for 28 days (group C)
Number of subjects: 54
Study 9272591 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide infusion
Number of subjects: 7
Study 9272591 — intervention group
Group type: COMPARATOR
Intervention: Control (without C-peptide)
Number of subjects: 7
Study 7618720 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of bupivacaine
Number of subjects: 52
Study 7618720 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms of sufentanil
Number of subjects: 52
Study 7618720 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of bupivacaine plus 10 micrograms of sufentanil
Number of subjects: 52
Study 7618720 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of bupivacaine and 10 micrograms of sufentanil
Number of subjects: 52
Study 2144206 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex depot supplemented by flutamide 250 mg 3 qid
Number of subjects: 327
Study 2144206 — intervention group
Group type: COMPARATOR
Intervention: Bilateral orchiectomy
Number of subjects: 327
Study 318577 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid antacid
Number of subjects: 30
Study 318577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31585971 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered wound assessment tool in addition to standard postoperative care
Number of subjects: 500
Study 31585971 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care
Number of subjects: 500
Study 28283485 — intervention group
Group type: EXPERIMENTAL
Intervention: QUIT EMR score (Quality of interhospital critical care transportation)
Number of subjects: 3000
Study 28283485 — intervention group
Group type: EXPERIMENTAL
Intervention: SEMROS (Simplified EMR outcome score)
Number of subjects: 3000
Study 26161601 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Composite Resin (HCR)
Number of subjects: 41
Study 26161601 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin Modified Glass Ionomer Cement (RMGIC)
Number of subjects: 41
Study 26161601 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer
Number of subjects: 41
Study 26161601 — intervention group
Group type: EXPERIMENTAL
Intervention: Giomer Composite Resin (GCR)
Number of subjects: 41
Study 24935051 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO(3); TUMS(®))
Number of subjects: 0
Study 24935051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (HCl; Renagel(®))
Number of subjects: 0
Study 24935051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole sodium (Protonix(®))
Number of subjects: 0
Study 22038523 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4‐8 mg/day
Number of subjects: 1332
Study 22038523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30‐45 mg/day
Number of subjects: 1332
Study 22038523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1332
Study 22038523 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 1,000 IU/day
Number of subjects: 1332
Study 20308972 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of arginine ingested in a single dose 60 minutes prior to exercise
Number of subjects: 6
Study 20308972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 20308972 — intervention group
Group type: COMPARATOR
Intervention: Arginine and placebo trials
Number of subjects: 6
Study 17640944 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-hMG
Number of subjects: 731
Study 17640944 — intervention group
Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 731
Study 16291760 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic protein N (10, 30, or 100 microg/dose)
Number of subjects: 69
Study 16291760 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic protein R (10, 30, or 100 microg/dose)
Number of subjects: 69
Study 16291760 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic protein C (10, 30, or 100 microg/dose)
Number of subjects: 69
Study 16291760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 12165692 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance+Strength (ES) training
Number of subjects: 15
Study 12165692 — intervention group
Group type: COMPARATOR
Intervention: Endurance-only (E) training
Number of subjects: 15
Study 9479340 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoRich liquid-based preparation (AutoCyte, Inc.)
Number of subjects: 0
Study 9479340 — intervention group
Group type: COMPARATOR
Intervention: Conventional smear
Number of subjects: 0
Study 8558939 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg/m2 orally)
Number of subjects: 46
Study 8558939 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (one dose)
Number of subjects: 46
Study 8558939 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (concomitant with methotrexate therapy)
Number of subjects: 46
Study 8558939 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate therapy only
Number of subjects: 46
Study 1888308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 80
Study 1888308 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 80
Study 6184574 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nitrendipine
Number of subjects: 12
Study 6184574 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg nitrendipine
Number of subjects: 12
Study 6184574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31599256 — intervention group
Group type: EXPERIMENTAL
Intervention: F-75 and F-100 recipes
Number of subjects: 92
Study 31599256 — intervention group
Group type: COMPARATOR
Intervention: Prepackaged F-75 & F-100 formulae
Number of subjects: 92
Study 28877748 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2586881 (0.4 mg/kg) administered twice daily for 3 days
Number of subjects: 39
Study 28877748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 26071863 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-Based Tracking Group (Fitbit intervention)
Number of subjects: 51
Study 26071863 — intervention group
Group type: COMPARATOR
Intervention: Pedometer Group (Control)
Number of subjects: 51
Study 23602601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab, and docetaxel
Number of subjects: 808
Study 23602601 — intervention group
Group type: COMPARATOR
Intervention: Placebo, trastuzumab, and docetaxel
Number of subjects: 808
Study 21825268 — intervention group
Group type: EXPERIMENTAL
Intervention: COM‐ON‐p (concise and individualized communication skills training)
Number of subjects: 41
Study 21825268 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 41
Study 19255706 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 81
Study 19255706 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric tube nutrition (NGTN)
Number of subjects: 81
Study 17129383 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel at a dose of 175, 210, or 250 mg/m2
Number of subjects: 474
Study 15577337 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial forearm flap
Number of subjects: 41
Study 15577337 — intervention group
Group type: COMPARATOR
Intervention: Thinned anterolateral thigh cutaneous flap
Number of subjects: 41
Study 11401123 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg daily for 12 weeks
Number of subjects: 90
Study 11401123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 1485787 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofragmentable intraluminal ring (Valtrac)
Number of subjects: 20
Study 1485787 — intervention group
Group type: COMPARATOR
Intervention: Suture of the cholecystointestinal anastomosis
Number of subjects: 20
Study 6695162 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting beta blocker (oxprenolol R 160 mg)
Number of subjects: 12
Study 6695162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6695162 — intervention group
Group type: COMPARATOR
Intervention: Basic conditions
Number of subjects: 12
Study 30807294 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dual therapy
Number of subjects: 232
Study 30807294 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy
Number of subjects: 232
Study 30333004 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent positive psychology intervention ('Living well with bipolar disorder') in addition to usual care (CAU)
Number of subjects: 112
Study 30333004 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CAU)
Number of subjects: 112
Study 27351244 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 194
Study 24615215 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese traditional healthcare exercises (CTHE)
Number of subjects: 136
Study 24615215 — intervention group
Group type: COMPARATOR
Intervention: the 8th radio calisthenics (control)
Number of subjects: 136
Study 22773713 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 97
Study 22773713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 22773713 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label Azithromycin
Number of subjects: 97
Study 20190028 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2 x 600 mg/daily for 8 weeks
Number of subjects: 30
Study 20190028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18681082 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rodent-specific environmental intervention
Number of subjects: 150
Study 15823451 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened version of the ACQ (symptoms alone)
Number of subjects: 552
Study 15823451 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened version of the ACQ (symptoms plus FEV1)
Number of subjects: 552
Study 15823451 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened version of the ACQ (symptoms plus short‐acting beta2‐agonist)
Number of subjects: 552
Study 15823451 — intervention group
Group type: EXPERIMENTAL
Intervention: Original ACQ
Number of subjects: 552
Study 15823451 — intervention group
Group type: EXPERIMENTAL
Intervention: All four versions of the ACQ
Number of subjects: 552
Study 12753323 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal using Simulect (IL-2 receptor inhibitor)
Number of subjects: 23
Study 12753323 — intervention group
Group type: COMPARATOR
Intervention: Standard maintenance immunosuppression including prednisone
Number of subjects: 23